Nuvalent Inc (NUVL)vsRevolution Medicines Inc (RVMD)
NUVL
Nuvalent Inc
$123.96
0.00%
HEALTHCARE · Cap: $9.81B
RVMD
Revolution Medicines Inc
$205.15
+3.71%
HEALTHCARE · Cap: $39.87B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. NUVL earns a higher WallStSmart Score of 25/100 (F).
NUVL
Avoid25
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.3x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : NUVL
The primary concerns for NUVL are Price/Book, Revenue Growth, EPS Growth.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.38 — expect wider price swings.
NUVL is growing revenue faster at 0.0% — sustainability is the question.
NUVL generates stronger free cash flow (-92M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NUVL scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology, dedicated to the development of targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, Nuvalent aims to innovate therapeutics that specifically address genetic mutations linked to tumor proliferation, thus enhancing treatment efficacy while minimizing adverse effects. With a promising pipeline of selective therapies, the company is well-positioned to capitalize on the expanding precision oncology market, demonstrating its commitment to revolutionizing cancer treatment and improving patient outcomes.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?